A recent research has highlighted a groundbreaking discovery concerning the connection between HMGB1 released by mesothelial cells and the development of asbestos-induced mesothelioma.
Worldwide, millions of individuals have been exposed to asbestos, leading to the onset of mesothelioma – a malignancy with unmet therapeutic needs. The research shows how asbestos exposure induces the release of HMGB1 from mesothelial cells: this triggers a plethora of events – TNFα secretion, macrophage accumulation, and atypical mesothelial hyperplasia.
The significance of this study unveils a new role for HMGB1: it emerges not just as a biomarker, but as a potential therapeutic target. Targeting HMGB1 might pave the way for innovative therapies to intervene in the early stages of mesothelioma growth.
HMGBiotech has recently discussed mesothelioma topic, joining CICON 2023 through a poster presentation by Dr. Liam Colley.
CICON is the international reference meeting for scientists, clinicians, regulators, drug developers, and patient advocates.
Liam Colley’s speech about “The role of CXCR4 in Triggering Immunosurveillance in the Malignant Mesothelioma Tumor Environment” reaffirming the focus on how to face mesothelioma and to improve current immunotherapies.
HMGBiotech can provide all the information to help you make an informed decision for your research purposes involving HMGB1.
Discover our HMGB1 proteins and request a quotation
Read the full article about the study: https://www.pnas.org/doi/10.1073/pnas.2307999120
